Losartan result in more complete inhibition of AT1 receptor activation give reasons
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here is a complete, well-reasoned answer:
Why Losartan (ARBs) Results in More Complete Inhibition of AT₁ Receptor Activation
1. Direct Receptor Blockade vs. Upstream Enzyme Inhibition
ACE inhibitors (e.g., enalapril, ramipril) block the angiotensin-converting enzyme, which converts Angiotensin I → Angiotensin II. However, this does NOT completely prevent Angiotensin II formation because:
- There are non-ACE pathways that can still generate Angiotensin II - including enzymes like chymase, cathepsin G, and tonin - especially in cardiac and vascular tissue.
- ACE inhibitors only block one enzyme in the pathway, so Angiotensin II can still be produced via these alternative routes.
Losartan (ARB) acts downstream - it directly blocks the AT₁ receptor itself. So no matter how Angiotensin II is produced (whether via ACE or via chymase/other enzymes), it cannot activate the AT₁ receptor. This gives more complete blockade of Angiotensin II effects.
"They also have the potential for more complete inhibition of angiotensin action compared with ACE inhibitors because there are enzymes other than ACE that are capable of generating angiotensin II."
- Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 279
2. Active Metabolite (EXP 3174) Adds to Potency
Losartan is a prodrug. Approximately 14% of an oral dose is converted by CYP2C9 and CYP3A4 to its active metabolite EXP 3174, which is more potent than losartan itself as an AT₁ receptor antagonist. This metabolite has a longer half-life and contributes to sustained, high-affinity receptor blockade.
- Goodman & Gilman's Pharmacological Basis of Therapeutics
3. No Effect on Bradykinin - More Selective Blockade
ACE inhibitors also prevent breakdown of bradykinin (since ACE also degrades bradykinin). This leads to accumulation of bradykinin and substance P, causing:
- Dry cough
- Angioedema
ARBs/Losartan have no effect on bradykinin metabolism, making them more selective blockers of angiotensin effects, with fewer side effects.
4. Allows AT₂ Receptor Stimulation (Beneficial)
When Losartan blocks AT₁ receptors, angiotensin II levels actually rise due to loss of negative feedback. This excess Angiotensin II then preferentially stimulates AT₂ receptors (which are not blocked by ARBs), producing:
- Vasodilation
- Anti-proliferative effects
- Possible cardioprotective actions
ACE inhibitors reduce total Angiotensin II, so they blunt this potentially beneficial AT₂ stimulation.
Summary Table
| Feature | ACE Inhibitors | Losartan (ARBs) |
|---|---|---|
| Site of action | ACE enzyme (upstream) | AT₁ receptor (downstream) |
| Blocks non-ACE Ang II production? | ❌ No | ✅ Yes (receptor is blocked regardless) |
| Bradykinin accumulation | ✅ Yes (causes cough) | ❌ No |
| AT₁ receptor blockade | Indirect/incomplete | Direct/complete |
| AT₂ stimulation | Reduced | Preserved/enhanced |
| Active metabolite | No (mostly) | EXP 3174 (more potent) |
In short: Losartan blocks the AT₁ receptor directly, so even Angiotensin II produced by non-ACE pathways (chymase, cathepsin G, etc.) cannot exert its effects - giving truly complete AT₁ receptor inhibition, which ACE inhibitors cannot achieve by blocking only one enzyme upstream.
This is a shared conversation. Sign in to Orris to start your own chat.